RecruitingNot ApplicableNCT07503496
Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy
Sponsor
China Medical University Hospital
Enrollment
96 participants
Start Date
Apr 7, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy. The study will assess chemotherapy-related side effects, quality of life, tumor size, tumor antigens, and routine blood test parameters over 24 weeks of treatment.
Eligibility
Sex: FEMALEMin Age: 20 YearsMax Age: 65 Years
Inclusion Criteria1
- Breast cancer stage I-III
Exclusion Criteria1
- pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTBiobran supplementation
3 g Biobran per day for 24 weeks
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07503496
Related Trials
A Study of Language Interpretation Solutions for People With Breast Cancer
NCT067210658 locations
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
NCT068021721 location
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
NCT062686651 location
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
NCT068069301 location
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
NCT071882462 locations